IM Cannabis Corp (IMCC-CN) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Delayed Last Update

Volume

Day Low0.7200

Day High0.7500

Open:0.7300

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

IMC to transfer its Oranim Pharmacy shares back to the seller

IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market

Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market

IMC applauds the April 1st implementation of the new Israeli cannabis regulation, facilitating access for many new patients

IM Cannabis Reports 2023 Financial Results

IMC Expects Accelerated Growth in Germany from the Country's Groundbreaking Cannabis Legalization

IM Cannabis to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 28 at 9:00am ET

IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company

February 28, 2024

IM Cannabis Receives 180 Calendar Day Extension from the Nasdaq Stock Market to Regain Compliance with Bid Price Rule

January 31, 2024

IMC Reschedules the Final Payment of the Oranim Pharmacy Acquisition

January 12, 2024

IMC Announces the Conclusion of the Planning and Construction Legal Proceedings

January 2, 2024

New Israeli cannabis regulation, facilitating access for many new patients, scheduled for December 29, 2023, has been postponed by three months; Israeli Ministry of Health published a new report showing a surge in new medical cannabis patients in November

December 8, 2023

IM Cannabis Announces Receipt of Court Action

November 27, 2023

IM Cannabis Reports Third Quarter 2023 Financial Results

November 13, 2023

IM Cannabis to Report Third Quarter 2023 Financial Results on Monday, November 13 at 9:00am ET

November 8, 2023

IM Cannabis Releases a Message from the CEO about the Israel-Hamas War and announces securing C$1,390,000 in Short-Term Debt

October 13, 2023

IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer

October 10, 2023

IM Cannabis Announces CFO Departure

September 19, 2023

IM Cannabis Reports Second Quarter 2023 Financial Results

August 14, 2023

IMC welcomes new Israeli cannabis regulations which are about to change significantly, facilitating access for many new patients

August 11, 2023

IM Cannabis to Report Second Quarter 2023 Financial Results on Monday, August 14 at 9:00am ET

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

IM Cannabis Reports First Quarter 2023 Financial Results; Gross Profit Increased 46% Year-over-Year

IM Cannabis Completes Debt Settlement with L5 Capital

IM Cannabis to Report First Quarter 2023 Financial Results on Monday, May 15 at 9:00am ET

IM Cannabis Announces Units for Debt Settlement

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

IM Cannabis to Report Fourth Quarter & Full Year 2022 Financial Results on Wednesday, March 29 at 9:00am ET

Stocks in play: IM Cannabis Corp

IM Cannabis Announces Additional Restructuring Initiatives Designed to Drive Sustainable Profitability and Reduce Costs

IM Cannabis Closes Additional Tranche of LIFE Offering

February 16, 2023

Profile

IM Cannabis Corp is a Canada-based international medical cannabis company. It offers government-licensed cannabis products, from generic to GMP-certified and pharmaceutical-grade, for both wholesale and retail clients. The majority of its revenues are generated from sales of medical cannabis products to customers in Israel and recreational cannabis in Canada. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.